
Semaglutide & Tirzepatide Guide
These GLP-1 agonists combat obesity and diabetes—two accelerators of aging—by powerfully regulating appetite and blood sugar.
General Disclaimer
**Tirzepatide** (brand name Mounjaro) takes this a step further. It is a novel "twincretin" or dual agonist, targeting both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is another incretin hormone that also plays a role in glucose regulation and appetite. By activating both pathways simultaneously, Tirzepatide has demonstrated even more potent effects on both blood sugar control and weight loss than GLP-1 agonists alone in head-to-head clinical trials. From a longevity and biological age perspective, the impact of these medications is monumental. Obesity and metabolic dysfunction are two of the primary accelerators of aging, driving chronic inflammation, insulin resistance, and cardiovascular disease. By inducing substantial weight loss (often 15-20%+ of body weight) and dramatically improving key metabolic health markers, these drugs directly combat the root causes of many age-related diseases. Emerging research is also uncovering their potential direct benefits on cardiovascular health, kidney function, and inflammation, independent of their powerful weight loss effects.
Disclaimer
This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. Neither AgeWise AI nor the publisher of this content takes responsibility for possible health consequences of any person or persons reading or following the information in this educational content.